Pharmaceutical Industry Raises Issue with Cuomo's Drug Price Control Proposal

The pharmaceutical industry is pushing back against Governor Cuomo's prescription drug price control proposal, arguing that it would lead to cuts in research. And they are pointing the finger at insurance companies and companies known as pharmacy benefit managers for the high costs paid by patients. Peter Pitts is a former FDA Associate Commissioner for External Relations and is now President of the Center for Medicine in the Public Interest.

 
Sign Up for Our Email Newsletter

RECENT NEWS

Managed Care Magazine Launches Attack on Orphans

Managed Care Magazine Launches Attack on Orphans

As the FDALawBlog points out, in some cases, a single orphan drug designation can result in multiple periods of orphan dr...  Read more

Cut FDA red tape so doctors can better treat patients

Cut FDA red tape so doctors can better treat patients

Off-label prescribing has already has saved thousands of lives. The FDA ought to make it easier for doctors and patients ...  Read more

A Social Media Manifesto
  • Journal of Commercial Biotechnology
  • 01/01/2014

A Social Media Manifesto

...  Read more

DRUGWONKS BLOG